The US Food and Drug Administration cleared Qiagen's Ipsogen JAK2 RGQ PCR Kit for additional use in the diagnosis of all myeloproliferative neoplasms
The test runs on Qiagen's Rotor-Gene Q MDx system and is designed to qualitatively detect the JAK2 V617F/G1849T allele in genomic DNA from whole blood.
The study expands on the known genetic subtypes, shows that they are correlated with clinical outcome, and paves the way for better subtype-driven patient management.
A multistage GWAS suggests inherited SNPs at four sites in the genome can contribute to the risk of developing myeloproliferative neoplasms.
Researchers have found that the order in which TET2 and JAK2 mutations are acquired may impact drug response and disease progression.
The 95-gene test is for detecting leukemia, myelodysplastic syndromes, and myeloproliferative disorders and can return results in less than one week.
Qiagen said this week that it has signed an agreement with Eli Lilly to develop a companion diagnostic for an early-stage compound that Lilly is developing to treat blood cancer.
By Turna Ray
Qiagen and Eli Lilly have partnered to develop and commercialize a molecular diagnostic that will help pick out best responders to a blood cancer drug that is in early development in Lilly's pipeline.
The Leukemia and Lymphoma Society grant will fund genome-wide analysis research.
The acquisition will also bolster Qiagen's personalized medicine play through the addition of Ipsogen's extensive portfolio of personalized diagnostics and prognostics in the area of blood cancer.
Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.
Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.
Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.
In Nature this week: sequenced genomes of five additional Neanderthals, and more.